Alira Health Extends Global Market Access Capabilities Through Acquisition of Wellmera

Expanded market access expertise strengthens Alira Health’s suite of healthcare advisory services

 

News
Published on:
December 17, 2019

FRAMINGHAM, MA, USA – December 17, 2019 – Alira Health, a leading international healthcare and life sciences advisory firm, announced that it has acquired Wellmera, a healthcare consulting firm headquartered in Basel, Switzerland specializing in market access for the pharmaceutical and biotechnology industries. The acquisition will bring global expertise in market access, pricing and reimbursement, health economics, and real-world evidence to Alira Health’s suite of healthcare advisory services.

The collective organization will advance Alira Health’s mission of enabling healthcare transformation by supporting clients across their product and corporate life cycles, with services in product development, regulatory, clinical, strategic consulting, and transaction advisory. The Wellmera team brings a wealth of experience in helping clients develop evidence, devise pricing and market access approaches, and provide tailored strategies to local client affiliates in preparation for pricing and reimbursement negotiations around the world, with a focus on European markets.

We are thrilled to welcome Wellmera and their incredible team to Alira Health. This acquisition is an important step in achieving our vision of offering a full continuum of services, particularly in the critical areas of regulatory, clinical and market access,” said Gabriele Brambilla, CEO of Alira Health. “These expanded services will help us to deliver even greater value to our clients as they develop and bring to market the next generation of healthcare innovations.

The Wellmera team is excited to join Alira Health,” says Jean-François Ricci, PharmD PhD, President and Principal at Wellmera. “This partnership allows us to bring our market access expertise to a larger global organization, helping us to impact patient care on an even greater scale. We see many synergies with Alira Health’s lifecycle approach, and feel a strong connection in our passion for healthcare, our quality of work, and the culture of our teams.”

Jean-François Ricci will become Executive Vice President of Market Access and will lead Alira Health’s Market Access practice, covering pharma, biotech, and digital health in Europe and the United States.

About Wellmera:

Wellmera is a dynamic international consulting firm focused on market access, pricing and reimbursement, health economics, and real-world evidence. We help life sciences companies demonstrate value, optimize patient access, and realize the commercial opportunity for their products throughout the lifecycle.

Wellmera was established in 2011 in Basel, Switzerland and expanded in early 2018 to the US with offices in Cambridge, MA, and San Francisco, CA, leveraging synergies for global clients between Europe and the US.

To learn more about Alira Health's Market Access practice

Click here

Related news

Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
Events May 16, 2023
PSI 2023 Conference
We're excited to talk orphan drugs and rare diseases at the World Orphan Drug Congress in Washington, D.C.
Orphan Drug Pharma Rare Disease UK
Events May 15, 2023
World Orphan Drug Congress USA
We're excited to talk orphan drugs and rare diseases at the World Orphan Drug Congress in Washington, D.C.
Orphan Drug Pharma Rare Disease
Events May 15, 2023
BIO International Convention
We are excited to share that we will be attending the BIO International Convention in Boston. This leading industry event attracts biotechnology and pharma leaders for one week of intensive(...)
Biotech Pharma
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.